It’s been an intense but very productive 42nd European Society of Human Reproduction and Embryology (ESHRE) Congress – the world’s largest gathering of professionals in reproductive medicine and embryology, held at Excel London. 🌸 So many great conversations, catch-ups and new connections forged: all united by a shared mission to improve fertility outcomes in the …

FREEDOM trial reaches 100% patient consent. Calla Lily Clinical Care is pleased to share an important milestone in our NIHR funded FREEDOM clinical trial. In less than three months since recruitment began, FREEDOM has passed its safety stopping rule, and all target patient participants are now consented. More than half of total participants have also …

With our FREEDOM clinical trial making exciting progress– now 60% recruited — we are delighted to start receiving national media coverage for this important step towards a more patient-centric option for women suffering from threatened miscarriage. A big thank you to the Daily Mail for featuring Callavid® and our University Hospitals Coventry and Warwickshire (UHCW) …

Our colleagues Ewa Radziwon and Shaun Knights had a very productive few days at INDEX Nonwovens INDEX™26 in #Geneva, hosted by EDANA, the voice of nonwovens 🇨🇭 As the world’s leading nonwovens exhibition, it was important for Calla Lily Clinical Care to attend again: reconnecting with existing suppliers, meeting potential new partners, and exploring exciting …

It was recently World Clinical Trials Day, and our co-founder Lara took part in a special event hosted by SökerData and Covington & Burling LLP: 🔬 “Innovation in Action: Successful Women’s Clinical Trial Case Studies” 🧪 Lara shared the context, design and exciting early progress of our ongoing FREEDOM clinical trial evaluating Callavid® for threatened …

Original article here Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage by John Pinching | 7th May 2026 | News Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the company’s Callavid …

We are delighted and honoured that Callavid® has been named in this National Institute for Health and Care Research (NIHR) news story highlighting the role NIHR is playing in improving outcomes for women through the UK Government’s revised Women’s Health Strategy. 🇬🇧 As NIHR notes: “NIHR is funding ‘Callavid’ which if approved would be the …

Original article here by Ben Adams photo by TF-Images/Getty Images German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation intravaginal drug delivery approach. London-based Calla Lily is working on several applications for its Callavid product, a tampon-shaped device that can be used as …

We were delighted to host Alex Zabala Findlay, our NIHR (National Institute for Health and Care Research) Programme Manager, for a highly productive visit to our labs. 🔬 As his first visit to our facilities, it was a great opportunity to showcase our bespoke equipment and laboratory capabilities, walk through the R&D challenges we’ve successfully …

✨ Big congratulations to our board advisor Prof/Dr Annalisa Jenkins OBE on being recognised in the King’s New Year Honour’s List! Over more than 25 years, Annalisa has been an outstanding leader in the life sciences– building and guiding teams that have successfully taken programmes from early scientific discovery through clinical development, regulatory approval, and …